You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group
|
|---|---|
| Published in |
Annals of Oncology, August 2014
|
| DOI | 10.1093/annonc/mdu375 |
| Pubmed ID | |
| Authors |
T. Tandstad, O. Ståhl, U. Håkansson, O. Dahl, H.S. Haugnes, O.H. Klepp, C.W. Langberg, A. Laurell, J. Oldenburg, A. Solberg, K. Söderström, E. Cavallin-Ståhl, U. Stierner, R. Wahlquist, N. Wall, G. Cohn-Cedermark, on behalf of SWENOTECA |
| Abstract |
SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Peru | 1 | 1% |
| Unknown | 77 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 18% |
| Student > Master | 12 | 15% |
| Other | 11 | 14% |
| Student > Postgraduate | 6 | 8% |
| Student > Doctoral Student | 5 | 6% |
| Other | 11 | 14% |
| Unknown | 19 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 46 | 59% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Neuroscience | 2 | 3% |
| Unspecified | 1 | 1% |
| Chemical Engineering | 1 | 1% |
| Other | 4 | 5% |
| Unknown | 22 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 August 2014.
All research outputs
#16,580,596
of 25,374,917 outputs
Outputs from Annals of Oncology
#6,033
of 7,854 outputs
Outputs of similar age
#136,811
of 242,846 outputs
Outputs of similar age from Annals of Oncology
#104
of 139 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,854 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,846 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 139 others from the same source and published within six weeks on either side of this one. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.